ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

BACKGROUND: ABX464 (obefazimod) is a small molecule that upregulates a single microRNA (miR-124) in immune cells and reduces the production of various inflammatory cytokines and chemokines. OBJECTIVE: We assessed the efficacy and safety of the standard of care (SoC) plus oral obefazimod (SoC plus AB...

Descripción completa

Detalles Bibliográficos
Autores principales: Giavina-Bianchi, Pedro, Cua, Eric, Risso, Karine, Mondain, Véronique, Vissian, Anaïs, Joie, Cécile, Pouletty, Philippe, Gineste, Paul, Ehrlich, Hartmut J., Kalil, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509999/
https://www.ncbi.nlm.nih.gov/pubmed/37781656
http://dx.doi.org/10.1016/j.jacig.2023.100140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509999/
https://www.ncbi.nlm.nih.gov/pubmed/37781656
http://dx.doi.org/10.1016/j.jacig.2023.100140

Ejemplares similares